Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

CHMP Okays Samsung's Infliximab Biosimilar

This article was originally published in Scrip

Executive Summary

Samsung Bioepis' infliximab biosimilar, Flixabi, has won a green light from the European Medicines Agency's Committee for Medicinal Products for Human Use. The CHMP is recommending it be approved for a range of indications: rheumatoid arthritis, adult and pediatric Crohn's disease, ulcerative colitis, pediatric ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and psoriasis.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register